BiBLOCK-TandAbs® — Simultaneous inhibition of two signaling pathways can create new treatment approaches.
The second pillar of Affimed´s TandAb® technology is the category of BiBLOCK-TandAbs®. It is well known that signaling pathways often work synergistically to enhance activation or inhibition. Especially in inflammatory diseases and allergic disorders, the synergistic role of chemokine interactions is well established and is currently the focus of new therapeutic approaches. The unique advantage of Affimed´s tetravalent BiBLOCK-TandAbs® is the simultaneous blocking of two targets by two binding sites for each target, thus ensuring high avidity when compared to bivalent constructs. This mode of action results in a strong blocking or inhibiting signal that is able to intervene, for example, in inflammatory or allergic diseases.
This technology platform will facilitate the generation of individually constructed TandAbs® against diverse disease targets.
Example for mode of Action of BiBLOCK TandAbs®
Cytokine/cytokine and chemokine /chemokine receptor signaling pathways play a pivotal role in the manifestation and progression of autoimmune diseases such as rheumatoid arthritis, inflammatory bowel disease, skin, and inflammation.